|
PT3056515T
(pt)
|
2008-01-15 |
2019-07-19 |
Univ Leland Stanford Junior |
Métodos para manipulação da fagocitose mediada por cd47
|
|
MX2015007446A
(es)
|
2012-12-12 |
2015-12-07 |
Vasculox Inc |
Anticuerpos terapeuticos para cd47.
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
JP6335189B2
(ja)
|
2012-12-17 |
2018-05-30 |
トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療
|
|
WO2016015095A1
(en)
*
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
CA2964173A1
(en)
*
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
AU2015350190B2
(en)
*
|
2014-11-18 |
2021-08-05 |
Janssen Pharmaceutica Nv |
CD47 antibodies, methods, and uses
|
|
ES2969389T3
(es)
*
|
2014-12-05 |
2024-05-17 |
Regeneron Pharma |
Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
AU2016225993B2
(en)
*
|
2015-03-04 |
2020-09-24 |
Yuhan Corporation |
Antibody therapeutics that bind CD47
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
JP7198083B2
(ja)
|
2015-08-26 |
2022-12-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
|
|
EP3347051A4
(en)
*
|
2015-09-10 |
2019-04-24 |
Affigen, Inc. |
SEQUENCING SELECTING TUMOR THEROSTICAS
|
|
BR112018005322A2
(pt)
|
2015-09-18 |
2018-12-11 |
Arch Oncology, Inc. |
anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
|
|
CN108290948B
(zh)
|
2015-09-21 |
2021-10-29 |
伊拉兹马斯大学医疗中心 |
抗-cd47抗体及使用方法
|
|
WO2017088012A1
(en)
|
2015-11-27 |
2017-06-01 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス， インコーポレイテッド |
グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
|
|
EA038880B1
(ru)
|
2016-01-11 |
2021-11-01 |
Форти Севен, Инк. |
Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
|
|
JP7026047B2
(ja)
*
|
2016-01-21 |
2022-02-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫調節剤を併用するがんの治療
|
|
AU2017250029C1
(en)
*
|
2016-04-15 |
2022-03-24 |
Pfizer Inc. |
Macrophage stimulation in CD47 blockade therapy
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
EP3487522A4
(en)
|
2016-07-19 |
2020-04-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
|
WO2018075857A1
(en)
|
2016-10-20 |
2018-04-26 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
US11446315B2
(en)
|
2016-11-03 |
2022-09-20 |
Pf Argentum Ip Holdings Llc |
Enhancement of CD47 blockade therapy by proteasome inhibitors
|
|
CN108779179B
(zh)
*
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
JP7117311B2
(ja)
*
|
2017-01-26 |
2022-08-12 |
ゼットリップ ホールディング リミテッド |
Ｃｄ４７抗原結合単位およびその使用
|
|
KR20190133198A
(ko)
*
|
2017-03-27 |
2019-12-02 |
셀진 코포레이션 |
면역원성의 감소를 위한 방법 및 조성물
|
|
US20200157179A1
(en)
*
|
2017-03-28 |
2020-05-21 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
US11168326B2
(en)
|
2017-07-11 |
2021-11-09 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
AU2018312222B2
(en)
|
2017-08-02 |
2024-11-21 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
ES2983651T3
(es)
*
|
2017-08-18 |
2024-10-24 |
Centessa Pharmaceuticals Uk Ltd |
Agentes de unión
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
KR102776457B1
(ko)
*
|
2017-10-18 |
2025-03-06 |
포티 세븐, 엘엘씨 |
항-cd47 작용제-기초된 난소암 요법
|
|
EP3704157A1
(en)
|
2017-11-01 |
2020-09-09 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Cd47 antigen-binding molecules
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
US11771764B2
(en)
|
2017-11-06 |
2023-10-03 |
Pfizer Inc. |
CD47 blockade with radiation therapy
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
WO2019200462A1
(en)
*
|
2018-04-16 |
2019-10-24 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
CN118147029A
(zh)
|
2018-07-11 |
2024-06-07 |
阿克蒂姆治疗有限公司 |
工程化的免疫刺激性细菌菌株及其用途
|
|
EP3836960A4
(en)
*
|
2018-08-13 |
2022-05-11 |
Arch Oncology, Inc. |
THERAPEUTIC CD47 ANTIBODIES
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
US11987627B2
(en)
|
2018-08-31 |
2024-05-21 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
Anti-CD47 antibody and application thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AU2019370031A1
(en)
*
|
2018-10-29 |
2021-05-27 |
Umc Utrecht Holding B.V. |
IgA mediated killing of aberrant cells by CD47- SIRPα checkpoint inhibition of neutrophils
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN113166257B
(zh)
*
|
2018-12-03 |
2023-05-30 |
上海开拓者生物医药有限公司 |
Cd47抗体及其制备方法和应用
|
|
MX2021010531A
(es)
|
2019-03-06 |
2021-10-01 |
Jiangsu Hengrui Medicine Co |
Proteina de fusion bifuncional y uso farmaceutico de la misma.
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
JP7561775B2
(ja)
|
2019-06-07 |
2024-10-04 |
エーエルエックス オンコロジー インコーポレイテッド |
血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
JP7317148B2
(ja)
|
2019-06-19 |
2023-07-28 |
レプ バイオファーマ カンパニー リミテッド |
抗ｃｄ４７抗体およびその使用
|
|
EP3999107A1
(en)
|
2019-07-16 |
2022-05-25 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
WO2021018114A1
(zh)
*
|
2019-07-30 |
2021-02-04 |
中山康方生物医药有限公司 |
抗人p40蛋白域抗体及其用途
|
|
KR20220053665A
(ko)
*
|
2019-09-03 |
2022-04-29 |
아케소 바이오파마, 인크. |
항-cd47 단일클론 항체 및 이의 용도
|
|
KR20220097875A
(ko)
|
2019-09-03 |
2022-07-08 |
마이얼로이드 테라퓨틱스, 인크. |
게놈 통합을 위한 방법 및 조성물
|
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
JP7520972B2
(ja)
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
MX2022005123A
(es)
|
2019-10-31 |
2022-05-30 |
Forty Seven Inc |
Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
|
|
EP4061420A1
(en)
*
|
2019-11-20 |
2022-09-28 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
AU2021250200A1
(en)
*
|
2020-04-02 |
2022-12-01 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antigen-binding polypeptide binding to CD47, and use thereof
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
CA3200514A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
AU2021373781A1
(en)
*
|
2020-11-04 |
2023-06-22 |
The Trustees Of Dartmouth College |
Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
|
|
MX2023005201A
(es)
|
2020-11-04 |
2023-06-28 |
Myeloid Therapeutics Inc |
Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
|
|
US20220196651A1
(en)
|
2020-12-06 |
2022-06-23 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
AU2022222994B2
(en)
*
|
2021-02-19 |
2025-11-27 |
Shaperon Inc. |
Single domain antibody against cd47 and use thereof
|
|
US20220305100A1
(en)
|
2021-03-12 |
2022-09-29 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
EP4337268A4
(en)
|
2021-05-11 |
2025-06-04 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686086B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2025509662A
(ja)
|
2022-03-24 |
2025-04-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｒｏｐ－２発現がんを治療するための併用療法
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences Inc |
CD73 COMPOUNDS
|
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|